115 related articles for article (PubMed ID: 10530414)
1. Natural effector cells in patients with acute myeloid leukemia treated with the immunomodulator Linomide after autologous bone marrow transplantation.
Hokland M; Jørgensen H; Holm MS; Simonsson B; Nilsson B; Bengtsson M; Hokland P
Eur J Haematol; 1999 Oct; 63(4):251-8. PubMed ID: 10530414
[TBL] [Abstract][Full Text] [Related]
2. Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation.
Simonsson B; Tötterman T; Hokland P; Lauria F; Carella AM; Fernandez MN; Rozman C; Ferrant A; de Witte T; Zander AR; Meier K; Hansson F; Nilsson BI
Bone Marrow Transplant; 2000 Jun; 25(11):1121-7. PubMed ID: 10849523
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia.
Bengtsson M; Simonsson B; Carlsson K; Nilsson B; Smedmyr B; Termander B; Oberg G; Tötterman TH
Transplantation; 1992 Apr; 53(4):882-8. PubMed ID: 1566354
[TBL] [Abstract][Full Text] [Related]
4. The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors.
Condiotti R; Slavin S; Barak V; Nagler A
Leuk Res; 1996 Jan; 20(1):57-63. PubMed ID: 8632678
[TBL] [Abstract][Full Text] [Related]
5. Autografting in chronic myelogenous leukemia followed by immunotherapy.
Rowe J; Ryan D; Dipersio J; Gaspari A; Nilsson B; Larsson L; Liesveld J; Kouides P; Simonsson B
Stem Cells; 1993 Oct; 11 Suppl 3():34-42. PubMed ID: 8298476
[TBL] [Abstract][Full Text] [Related]
6. Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide.
Rowe JM; Nilsson BI; Simonsson B
Leuk Lymphoma; 1993 Nov; 11(5-6):321-9. PubMed ID: 7510190
[TBL] [Abstract][Full Text] [Related]
7. Dermatologic changes associated with roquinimex immunotherapy after autologous bone marrow transplant.
Ohsuga Y; Rowe JM; Liesveld J; Burns RP; Gaspari AA
J Am Acad Dermatol; 2000 Sep; 43(3):437-41. PubMed ID: 10954654
[TBL] [Abstract][Full Text] [Related]
8. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
9. Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex.
Vaz F; Silva MR; Ascensao JL
Br J Cancer; 1995 Dec; 72(6):1498-503. PubMed ID: 8519666
[TBL] [Abstract][Full Text] [Related]
10. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level.
Kalland T
J Immunol; 1990 Jun; 144(11):4472-6. PubMed ID: 2341727
[TBL] [Abstract][Full Text] [Related]
11. The first clinical pilot study of roquinimex (Linomide) in cancer patients with special focus on immunological effects.
Bergh JC; Tötterman TH; Termander BC; Strandgarden KA; Gunnarsson PO; Nilsson BI
Cancer Invest; 1997; 15(3):204-11. PubMed ID: 9171853
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).
Karussis DM; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Kalland T; Abramsky O
Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6400-4. PubMed ID: 8341645
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex.
Rowe JM; Rapoport AP; Ryan DH; Nilsson BI; Duerst RE; Packman CH; Abboud CN; DiPersio JF; Linder T; Wang N; Simonsson B; Liesveld JL
Bone Marrow Transplant; 1999 Nov; 24(10):1057-63. PubMed ID: 10578155
[TBL] [Abstract][Full Text] [Related]
14. Linomide administration following bone marrow transplantation in mice.
Weiss L; Abdul-Hai A; Shufaro Y; Reich S; Slavin S
Cancer Immunol Immunother; 2002 Dec; 51(11-12):596-602. PubMed ID: 12439604
[TBL] [Abstract][Full Text] [Related]
15. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation.
Karussis DM; Meiner Z; Lehmann D; Gomori JM; Schwarz A; Linde A; Abramsky O
Neurology; 1996 Aug; 47(2):341-6. PubMed ID: 8757002
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
18. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide.
Karussis DM; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Ben-Nun A; Kalland T; Abramsky O
Ann Neurol; 1993 Nov; 34(5):654-60. PubMed ID: 8239559
[TBL] [Abstract][Full Text] [Related]
20. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Klingemann HG; Deal H; Reid D; Eaves CJ
Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
